指南与共识血栓与止血

ISTH指南:需体外循环心脏手术的HIT患者抗凝管理

Management of anticoagulation in patients with heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: guidance from the ISTH SSC on Perioperative and Critical Care Haemostasis and Thrombosis.
指南 / 共识 · J Thromb Haemost · 2026-06-04

肝素诱导的血小板减少症(HIT)患者需体外循环心脏手术时抗凝管理困难。ISTH SSC系统综述筛选1732篇文献纳入30项研究,评估直接凝血酶抑制剂、血浆置换后普通肝素(UFH)、UFH联合强效抗血小板药及功能试验阴性者再暴露等策略。比伐卢定证据最强但出血风险高且无逆转剂;血浆置换可降低抗体滴度允许术中UFH使用;功能试验阴性者有限再暴露复发风险低。

要点

  • 比伐卢定证据最强但出血风险高且无逆转剂
  • 血浆置换可降低抗PF4/肝素抗体滴度,允许术中UFH使用
  • 功能试验阴性者有限术中UFH再暴露复发风险低,需术后监测

核心结论

  • HIT患者体外循环心脏手术的抗凝策略需多学科个体化决策,比伐卢定证据最强但出血风险高且无逆转剂。
  • 血浆置换联合或不联合静脉免疫球蛋白可降低抗体滴度并允许术中UFH使用,但方案异质。
  • 功能试验阴性者有限术中UFH再暴露复发风险低,需术后监测。

研究设计与样本

  • ISTH SSC围术期与危重症止血与血栓形成指南,基于系统综述与写作组共识制定。
  • 系统综述筛选1732篇文献,纳入30项研究,评估HIT病史患者体外循环心脏手术的术中抗凝策略。

主要发现

  • 评估策略包括直接凝血酶抑制剂、术前或术中治疗性血浆置换后UFH、UFH联合强效抗血小板药、功能试验阴性者肝素再暴露。
  • 比伐卢定支持数据最强且似乎有效,但与出血增加相关且缺乏逆转剂等实际限制影响其使用。
  • 血浆置换联合或不联合静脉免疫球蛋白降低抗血小板因子4/肝素抗体滴度,允许术中UFH使用,但方案异质。
  • UFH联合强效抗血小板药再暴露显示前景但有出血和低血压风险。
  • 功能试验阴性者有限术中UFH再暴露HIT复发风险低,需术后监测。

关键数值与推荐

  • 比伐卢定证据最强但出血风险高且无逆转剂。
  • 血浆置换可降低抗PF4/肝素抗体滴度并允许术中UFH使用,方案异质。
  • 功能试验阴性者有限UFH再暴露复发风险低,需术后监测。

临床怎么用

  • 比伐卢定可作为HIT患者体外循环心脏手术的抗凝选择,但需警惕出血且无逆转剂。
  • 可考虑术前或术中血浆置换联合或不联合静脉免疫球蛋白后使用UFH,需个体化评估。
  • 功能试验阴性者可考虑有限术中UFH再暴露,术后需监测HIT复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction characterized by thrombocytopenia and a high risk of thrombosis. Patients with HIT and a need for cardiac surgery with cardiopulmonary bypass represent a challenging group, as anticoagulation with unfractionated heparin (UFH) is the primary treatment choice. We conducted a systematic review evaluating intraoperative anticoagulation strategies for patients with a history of HIT who required cardiac surgery with cardiopulmonary bypass. Guidance statements were generated through consensus of the writing group. Of 1732 screened articles, 30 studies were included. Strategies evaluated were (1) direct thrombin inhibitors; (2) UFH after preoperative or intraoperative therapeutic plasma exchange (TPE); (3) UFH in combination with a potent antiplatelet agent; and (4) heparin reexposure in patients with negative functional assays. Of these, bivalirudin has the strongest supporting data and appears effective; still, its association with increased bleeding and practical limitations, including a lack of a reversal agent, limit its use. TPE with or without intravenous immunoglobulin reduces antiplatelet factor 4/heparin antibody titers and allows for intraoperative UFH use, although protocols are heterogeneous. Use of potent antiplatelet agents with UFH reexposure show promise but carry risks of bleeding and hypotension. Thus, alternative strategies of using UFH in combination with TPE or potent antiplatelet agents may be considered on a case-by-case basis. For patients with negative functional assays, evidence suggests that limited intraoperative UFH reexposure carries a low risk of HIT recurrence, provided postoperative monitoring is performed. These guidance statements provide a framework for multidisciplinary decision making in a complex clinical scenario.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Pishko AM, Frere C, Maier CL, et al. Management of anticoagulation in patients with heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: guidance from the ISTH SSC on Perioperative and Critical Care Haemostasis and Thrombosis. J Thromb Haemost. 2026. PMID: 42248416. doi:10.1016/j.jtha.2026.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。